Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prime Editor 3 Mediated Beta-Thalassemia Mutations of the HBB Gene in Human Erythroid Progenitor Cells.

International journal of molecular sciences - 30 Apr 2022

Zhang Haokun, Zhou Qinlinglan, Chen Hongyan, Lu Daru

Abstract excerpt

Recently developed Prime Editor 3 (PE3) has been implemented to induce genome editing in various cell types but has not been proven in human hematopoietic stem and progenitor cells. Using PE3, we successfully installed the beta-thalassemia (beta-thal) mutations in the HBB gene in the erythroid progenitor cell line HUDEP-2. We inserted the mCherry reporter gene cassette into editing plasmids, each including the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Globins
Share to beta-Globins
Share to beta-Thalassemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythroid Precursor Cells

Share to Gene Editing

Share to Hemoglobins

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35563395
DOI: 10.3390/ijms23095002
PMCID: PMC9099916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prime Editor 3 Mediated Beta-Thalassemia Mutations of the HBB Gene in Human Erythroid Progenitor Cells.PMID 35563395Read ↗

A Universal Approach to Target Various HBB Gene Mutations in Hematopoietic Stem/Progenitor Cells for Beta-Thalassemia Gene Therapy by CRISPR/Cas9 and the rAAV6 VectorSemantic proximity Read ↗

Precise correction of a spectrum of β-thalassemia mutations in coding and non-coding regions by base editorsSemantic proximity Read ↗

Base editing of β0-thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies.Semantic proximity Read ↗

Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin.Semantic proximity Read ↗

Enhanced fetal hemoglobin production via dual-beneficial mutation editing of the HBG promoter in hematopoietic stem and progenitor cells for β-hemoglobinopathies.Semantic proximity Read ↗

Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donorsSemantic proximity Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

Base editing of β <sup>0</sup> thalassemia mutations as a therapeutic strategy for β-hemoglobinopathies: efficacy and genotoxicity studiesSemantic proximity Read ↗

Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the <i>HBG1/2</i> promotersSemantic proximity Read ↗

Recent advancements in gene therapy for sickle cell disease and β-thalassemiaSemantic proximity Read ↗

Efficient repair of human homozygous genetic mutation by CRISPR/Cas9 mediated interlocus gene conversionSemantic proximity Read ↗

Prime editing in hematopoietic stem cells—From ex vivo to in vivo CRISPR-based treatment of blood disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.